EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

11-Oxygenated androgens in PCOS: impact of PCOS phenotypes and first-line interventions

Anuja Dokras iD, Allen R Kunselman, Christina M Stetter, Michael McPhaul, Frank Z Stanczyk, Richard S Legro

The Journal of Clinical Endocrinology & Metabolism · 13.08.2026

DOI: 10.1210/clinem/dgag329 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, online erschienen am 13.08.2026. Verfasst von Anuja Dokras und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, Division of Reproductive Endocrinology, Hospital of the University of Pennsylvania, Philadelphia, PA, USA. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Institutes of Health, NIH, Eunice Kennedy Shriver National Institute of Child Health and Human Development.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Context

Androgen excess in polycystic ovary syndrome (PCOS)/polyendocrine metabolic ovarian syndrome (PMOS) is classically attributed to ovarian steroids, yet adrenal-derived 11-oxygenated androgens are potent contributors whose regulation and treatment responsiveness in PMOS remains poorly characterized.

Objective

To quantify classic and 11-oxygenated androgens across PMOS phenotypes vs controls and to evaluate their responses to oral contraceptive pills (OCPs), metformin, or lifestyle modification (LSM).

Design

Secondary analysis of residual serum samples from 3 trials: oral contraceptives versus weight loss (OWL)–PCOS trial (16-week OCP vs LSM), combined OCPs versus metformin (COMET)–PCOS trial (24-week OCP vs metformin), and assessment of multiple intrauterine gestations from ovarian stimulation (AMIGOS) trial (controls).

Setting

Two academic medical centers. Patients or Other Participants Two hundred and seventy-six with Rotterdam-defined PMOS and 97 controls. Intervention(s) Low-dose OCPs (4-6 months), metformin (2000 mg/day for 6 months), or LSM (4 months). Main Outcome Measure(s) Serum concentrations of 11β-hydroxytestosterone (11-OHT), 11-ketotestosterone (11-KT), 11-ketoandrostenedione (11-KA4), and 11β-hydroxyandrostenedione (11-OHA4) measured by liquid chromatography–tandem mass spectrometry, and total testosterone (TT), at baseline and end of study.

Results

Adjusting for age and body mass index, women with PCOS/PMOS had higher median 11-OHT (11.0 vs 7.8 ng/dL; P = .01) and 11-KT (31.9 vs 25.6 ng/dL; P = .03) than controls. Elevations were phenotype specific: biochemical hyperandrogenism showed broad increases, whereas clinical hyperandrogenism with normal TT found no significant differences compared with controls. Oral contraceptive pills suppressed 11-KT, 11-KA4, and 11-OHT (all P < .001), comparable to TT reductions. Metformin produced modest reductions in 11-OHT and 11-KT (P < .05), while LSM had no effect. Changes were independent of body mass index, glycemia, and homeostatic model assessment for insulin resistance (HOMA-IR).

Conclusion

11-Oxygenated androgens are elevated in PMOS in a phenotype-specific manner and are strongly suppressed by OCPs, with modest response to metformin and no short-term effect from LSM, supporting their utility in phenotyping and treatment monitoring.

Schlagwörter

Stichwörter der Autor:innen

11-oxygenated androgensmetforminoral contraceptive pillspolycystic ovary syndrome/polyendocrine metabolic ovarian syndrome

Autor:innen und Institutionen

  • Department of Obstetrics and Gynecology, Division of Reproductive Endocrinology, Hospital of the University of Pennsylvania, Philadelphia, PA, USA.
  • Department of Public Health Sciences, Penn State College of Medicine, Hershey, PA, USA.
  • Department of Internal Medicine - Endocrinology, UT Southwestern, 5323 Harry Hines Blvd., Dallas, TX 75390, USA.
  • Department of Obstetrics and Gynecology, Keck School of Medicine of USC, Los Angeles, CA, USA.
  • Department of Obstetrics and Gynecology, Penn State College of Medicine, Hershey, PA, USA.

ORCID-Profile: Anuja Dokras

Förderung

  • National Institutes of Health
  • NIH
  • Eunice Kennedy Shriver National Institute of Child Health and Human Development
  • NICHD

Zitieren

APA

Dokras, A., Kunselman, A. R., Stetter, C. M., McPhaul, M., Stanczyk, F. Z., & Legro, R. S. (2026). 11-Oxygenated androgens in PCOS: impact of PCOS phenotypes and first-line interventions. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/clinem/dgag329

Vancouver

Dokras A, Kunselman AR, Stetter CM, McPhaul M, Stanczyk FZ, Legro RS. 11-Oxygenated androgens in PCOS: impact of PCOS phenotypes and first-line interventions. The Journal of Clinical Endocrinology & Metabolism. 2026. doi:10.1210/clinem/dgag329

BibTeX
@article{Dokras2026,
  author = {Dokras, Anuja and Kunselman, Allen R and Stetter, Christina M and McPhaul, Michael and Stanczyk, Frank Z and Legro, Richard S},
  title = {11-Oxygenated androgens in PCOS: impact of PCOS phenotypes and first-line interventions},
  journal = {The Journal of Clinical Endocrinology & Metabolism},
  year = {2026},
  doi = {10.1210/clinem/dgag329}
}
Kostenlos starten →